Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 4231 AL 4245

Cerebral microbleeds as a biomarker in Alzheimer's disease? A review in the field

Shams S, Wahlund LO.

Biomark Med. 2016;10(1):9-18. doi: 10.2217/bmm.15.101. Epub 2015 Dec 7.

Seven-Tesla MRI and neuroimaging biomarkers for Alzheimer's disease

Ali R, Goubran M, Choudhri O, Zeineh MM.

Neurosurg Focus. 2015 Nov;39(5):E4. doi: 10.3171/2015.9.FOCUS15326.

Emergence of exosomal miRNAs as a diagnostic biomarker for Alzheimer's disease

Van Giau V, An SS.

J Neurol Sci. 2016 Jan 15;360:141-52. doi: 10.1016/j.jns.2015.12.005. Epub 2015 Dec 4.

A review of cognitive impairment and differential diagnosis in idiopathic normal pressure hydrocephalus

Picascia M, Zangaglia R, Bernini S, Minafra B, Sinforiani E, Pacchetti C.

Funct Neurol. 2015 Oct-Dec;30(4):217-28. doi: 10.11138/fneur/2015.30.4.217.

Alzheimer disease, inflammation, and novel inflammatory marker: resistin

Kizilarslanoğlu MC, Kara Ö, Yeşil Y, Kuyumcu ME, Öztürk ZA, Cankurtaran M, Rahatli S, Pakaştiçali N, Çinar E, Halil MG, Sener B, Cankurtaran ES, Arioğul S.

Turk J Med Sci. 2015;45(5):1040-6.

Potential genetic biomarkers in the early diagnosis of Alzheimer disease: APOE and BIN1

Kaya G, Gündüz E, Acar M, Hatipoğlu ÖF, Acar B, Ilhan A, Gündüz M.

Turk J Med Sci. 2015;45(5):1058-72.

Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease

Sirin FB, Kumbul Doğuç D, Vural H, Eren I, Inanli I, Sütçü R, Delibaş N.

Turk J Med Sci. 2015;45(5):1073-7. doi: 10.3906/sag-1406-134.

A Turkish 3-center study evaluation of serum folic acid and vitamin B12 levels in Alzheimer disease

Ulusu NN, Yilmaz G, Erbayraktar Z, Evlice AT, Aras S, Yener G, Avci A.

Turk J Med Sci. 2015;45(5):1159-66. doi: 10.3906/sag-1406-136.

Proteomics as an innovative tool to investigate frontotemporal disorders

Agresta AM, De Palma A, Bardoni A, Salvini R, Iadarola P, Mauri PL.

Proteomics Clin Appl. 2016 Apr;10(4):457-69. doi: 10.1002/prca.201500090. Epub 2015 Dec 10.

Early molecular changes in Alzheimer disease: can we catch the disease in its presymptomatic phase?

Wirz KT, Keitel S, Swaab DF, Verhaagen J, Bossers K.

J Alzheimers Dis. 2014;38(4):719-40. doi: 10.3233/JAD-130920.

A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease

Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, Waichunas D, Bumgarner L, Bourdette D, Silbert L, Kaye J.

J Alzheimers Dis. 2014;38(1):111-20. doi: 10.3233/JAD-130722.

The Centers for Medicare & Medicaid Services and amyloid-β positron emission tomography for Alzheimer disease

Steinbrook R.

JAMA Intern Med. 2014 Jan;174(1):135. doi: 10.1001/jamainternmed.2013.11705.

Amyloid-β positron emission tomography in the diagnostic evaluation of alzheimer disease: summary of primary findings and conclusions

Pearson SD, Ollendorf DA, Colby JA.

JAMA Intern Med. 2014 Jan;174(1):133-4. doi: 10.1001/jamainternmed.2013.11711.

Stroop effects in Alzheimer's disease: selective attention speed of processing, or color-naming? A meta-analysis

Ben-David BM, Tewari A, Shakuf V, Van Lieshout PH.

J Alzheimers Dis. 2014;38(4):923-38. doi: 10.3233/JAD-131244.

Art therapy for Alzheimer's disease and other dementias

Chancellor B, Duncan A, Chatterjee A.

J Alzheimers Dis. 2014;39(1):1-11. doi: 10.3233/JAD-131295.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias